3rd Quarter - Report

PARRY, ROMANI, DECONCINI & SYMMS for SANOFI US SERVICES INC (FORMERLY KNOWN AS SANOFI-AVENTIS U S INC )

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Financial Institutions/Investments/Securities FIN

Monitor legislation reforming the Committee on Foreign Investment in the United States process.

Foreign entity interest: sanofi-aventis U.S. Inc. is owned 100% by sanofi-aventis SA (France) and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so too sanofi-aventis SA, as its parent, will benefit.

LobbyistCovered position, as disclosed
EDWARD H BAXTER —
DENNIS DECONCINI —
JAMES ROCK —
ROMANO ROMANI —
THADDEUS E STROM —
STEVE SYMMS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Copyright/Patent/Trademark CPT

Oppose importation of unsafe drugs from outside the United States. Monitor S. 1145 and H.R. 1082, Patent Law Reform. Support amendments to strengthen patent enforcement.

Foreign entity interest: sanofi-aventis U.S. Inc. is owned 100% by sanofi-aventis SA (France) and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so too sanofi-aventis SA, as its parent, will benefit.

LobbyistCovered position, as disclosed
EDWARD H BAXTER —
DENNIS DECONCINI —
JAMES ROCK —
ROMANO ROMANI —
THADDEUS E STROM —
STEVE SYMMS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 1145 (110th), H.R. 1082 (110th)

Medical/Disease Research/Clinical Labs MED

Support efforts to obtain approval of at least one more compendia by the Department of Health and Human Services for use in Medicare reimbursement decisions for cancer medications. S. 1505 - Affordable Biologics for Consumers Act S. 1695 Biologics Price Competition and Innovation Act of 2007, support enactment and follow-on Biologics legislation with amendments that strengthen FDA pathway and provide data exclusivity. H.R. 1956 - Patient Protection and Innovative Biologic Medicines Act of 2007

Foreign entity interest: sanofi-aventis U.S. Inc. is owned 100% by sanofi-aventis SA (France) and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so too sanofi-aventis SA, as its parent, will benefit.

LobbyistCovered position, as disclosed
EDWARD H BAXTER —
DENNIS DECONCINI —
JAMES ROCK —
ROMANO ROMANI —
THADDEUS E STROM —
STEVE SYMMS —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 1505 (110th), H.R. 1956 (110th), S. 1695 (110th)

Law Enforcement/Crime/Criminal Justice LAW

Monitor legislation regulating agreements between pharmaceutical companies to settle patent infringement lawsuits.

Foreign entity interest: sanofi-aventis U.S. Inc. is owned 100% by sanofi-aventis SA (France) and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so too sanofi-aventis SA, as its parent, will benefit.

LobbyistCovered position, as disclosed
EDWARD H BAXTER —
DENNIS DECONCINI —
JAMES ROCK —
ROMANO ROMANI —
THADDEUS E STROM —
STEVE SYMMS —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.